In this Satellite, WHO will present highlights from recent updates to the Consolidated ARV guidelines. New directions on the role of dolutegravir (DTG) based regimens in first and second line treatment, and in post-exposure prophylaxis (PEP), as well as, directions to improve early infant diagnosis will be presented. Country approaches to the implementation of dolutegravir transition and data needs to help better understand the signal of neural tube defect (NTD) risk will be explored. A panel with representation from Ministries of Health, researchers, implementers and civil society will review the implications of these new directions for HIV treatment programmes. This session will be of interest to programme managers, researchers, implementers, clinicians and civil society. Lunch will be served prior to the satellite

• Presentations
• Map